1. A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications.
- Author
-
Patel AJ, Tan TM, Richter AG, Naidu B, Blackburn JM, and Middleton GW
- Subjects
- Aged, Autoantibodies immunology, Biomarkers, Tumor immunology, Carcinoma, Non-Small-Cell Lung blood, Carcinoma, Non-Small-Cell Lung immunology, Computational Biology methods, Female, Humans, Lung Neoplasms blood, Lung Neoplasms immunology, Male, Prognosis, ROC Curve, Autoantibodies blood, Biomarkers, Tumor blood, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms pathology, Protein Array Analysis methods
- Abstract
Background: Lung cancer is the leading cause of cancer-related death worldwide. Surgical resection remains the definitive curative treatment for early-stage disease offering an overall 5-year survival rate of 62%. Despite careful case selection, a significant proportion of early-stage cancers relapse aggressively within the first year post-operatively. Identification of these patients is key to accurate prognostication and understanding the biology that drives early relapse might open up potential novel adjuvant therapies., Methods: We performed an unsupervised interrogation of >1600 serum-based autoantibody biomarkers using an iterative machine-learning algorithm., Results: We identified a 13 biomarker signature that was highly predictive for survivorship in post-operative early-stage lung cancer; this outperforms currently used autoantibody biomarkers in solid cancers. Our results demonstrate significantly poor survivorship in high expressers of this biomarker signature with an overall 5-year survival rate of 7.6%., Conclusions: We anticipate that the data will lead to the development of an off-the-shelf prognostic panel and further that the oncogenic relevance of the proteins recognised in the panel may be a starting point for a new adjuvant therapy., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF